Homepage Top Section1

The committee has recommended the approval of Tecentriq plus chemotherapy (carboplatin and Abraxane [albumin-bound paclitaxel; nab-paclitaxel]) for the initial treatment of adults with metastatic non-squamous non-small cell lung

The part one of the phase 3 CheckMate -227 trial assessing Opdivo plus low-dose Yervoy (ipilimumab) achieved the co-primary endpoint of overall survival (OS). According to the company,

Ruxience, a monoclonal antibody (mAb), has been approved to treat non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukaemia (CLL), and granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). Ruxience works

Myxredlin is claimed to be the first and only ready-to-use insulin for intravenous (IV) infusion in the hospital and other acute care settings. It is provided with an

Otezla (apremilast) 30mg is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4), particularly for cyclic adenosine monophosphate (cAMP). It is claimed to be the first and only approved

The FDA has approved Recarbrio to treat patients 18 years of age and older who have limited or no alternative treatment options for cUTI, including pyelonephritis, caused by

In January 2018, the company announced that crizanlizumab was granted breakthrough therapy designation by the FDA. Novartis’ application for the investigational drug is backed by results from a

Last month, a phase 3 trial called CASPIAN met its primary endpoint with Imfinzi by delivering a statistically-significant and clinically-meaningful improvement in overall survival for patients suffering from

An investigational monoclonal antibody, isatuximab, has been designed to target a specific epitope on the CD38 receptor of a plasma cell. The drug has been designed to activate